183 related articles for article (PubMed ID: 36750899)
1. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H
Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899
[TBL] [Abstract][Full Text] [Related]
2. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
4. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
[TBL] [Abstract][Full Text] [Related]
6. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y
Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042
[TBL] [Abstract][Full Text] [Related]
7. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.
Zhang T; Zhang Y; Zhou L; Deng S; Huang M; Liu Y; Liu Y; Gong Y; Zhu J; Xue J; Bai Y; Ma H; Zhang Y; Yu M; Li Y; Wang Y; Zou B; Zhou X; Xiu W; Na F; Xu Y; Peng F; Wang J; Lu Y
Cancer Med; 2020 Dec; 9(23):8772-8781. PubMed ID: 33027555
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
10. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Yu X; Fan Y
J Cancer; 2019; 10(15):3486-3493. PubMed ID: 31293653
[No Abstract] [Full Text] [Related]
15. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
16. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Lung-Mol Graded Prognostic Assessment (GPA) System for the Prognosis of Patients Receiving Radiotherapy for Brain Metastasis From Non-small Cell Lung Cancer.
Toriduka D; Matsuo Y; Hanazawa H; Kishi N; Uto M; Mizowaki T
Cureus; 2024 Apr; 16(4):e57485. PubMed ID: 38707125
[TBL] [Abstract][Full Text] [Related]
18. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
19. Prognostic value of cranial radiotherapy and optimal timing stratified by lung-molGPA for NSCLC patients with brain metastases.
Jia W; Zhai X; Jing X; Bao Q; Xu S; Zhu H; Wu G; Yu J
J Neurooncol; 2023 Sep; 164(2):321-330. PubMed ID: 37648933
[TBL] [Abstract][Full Text] [Related]
20. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
